PubMed Health⌕ Search

Biomedical subjects

K Nabeya

Publications and source records attributed to K Nabeya.

At least 19 recordsLinked to original sources
PubMed1997

Extent of resection and lymphadenectomy in early squamous cell esophageal cancer.

To decide the extent of resection and lymphadenectomy in early esophageal cancer, accurate diagnosis at the preoperative stage is essential. Because in mucosal cancer lymph node metastasis is hardly ever seen, minimal invasive surgery, by endoscopic mucosal resection is indicated. On the other hand, for submucosal cancer lymph node metastasis the rate is as high as 26-45%, therefore, standard resection and systematic lymphadenectomy is indicated, corresponding to that for advanced cancer. In Japan the 5-year survival rate after resection is 98-100% for mucosal cancer and 67-90% for submucosal cancer.

Carcinoma, Squamous Cell↗
PubMed1993

What is the ideal treatment for early esophageal cancer?

A study was made of treatment policies for superficial cancer in 1,982 cases in Japan from 1966 to 1989, and on 45 cases experienced in our department. The majority of epithelial cancer and muscularis mucosal cancer was early cancer without lymph node metastasis, and the five-year survival rates, excluding other disease deaths, was approximately 90-95%. It was estimated that reduced surgery would be sufficient. In high risk cases, and for patients rejecting surgery, radiotherapy with chemotherapy was acceptable. In submucosal cancer, node metastasis existed in approximately 35% of cases, and the five-year survival rates, excluding other disease deaths, was approximately 60%. However, even though a case may be node negative, some develop recurrent disease and for this reason radical surgery, as applicable in advanced cancer cases, is desirable.

Combined Modality Therapy↗
PubMed1993

[Multidisciplinary treatment principles for improved QOL in patients with esophageal cancer].

We recently performed multidisciplinary treatment for improved QOL in patients with esophageal cancer according the following principles: 1. The expected preoperative diagnosis of staging for esophageal cancer is performed by preoperative examinations, and the plan for perioperative combined therapy is established. 2. For intraepithelial cancer (ep) and lamina propria mucosal cancer (mm), small stress treatment is the choice. For submucosal cancer (sm), esophagectomy with right thoracotomy and lymph node dissection are performed as a rule, but where negative lymph node metastasis is inferred by preoperative examination, esophagectomy without thoracotomy (blunt dissection) and postoperative adjuvant therapy are performed. 3. For advanced esophageal cancer, adjuvant therapy is performed as far as possible in consideration of depth of invasion, lymph node metastasis and general condition. 4. For far advanced esophageal cancer, esophageal prosthesis intubation is the first choice, and adjuvant therapy is performed in patients with a relatively fair general condition.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1992

[A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group].

A phase II clinical study of 254-S, a new anticancer platinum complex for gastrointestinal cancers, was conducted by the 254-S Gastrointestinal Cancer Study Group consisting of 16 institutions. 254-S was administered at 100 mg/m2 by intravenous drip infusion. This administration was repeated at 4-week intervals. The cases in which 254-S could be administered at least two times were regarded as complete cases evaluable for tumor response; of 75 cases registered, 53 were complete cases (29 cases with esophageal cancer, 12 with stomach cancer and 12 with colon cancer). As a result, 15 partial responses (PR) were obtained in the 29 patients with esophageal cancer and 1 PR from the 12 patients with stomach cancer, for a 51.7% and 8.3% response rate, respectively. 5 PR (55.6%) were obtained in 9 esophageal cancer patients with prior chemotherapy, including 2 PR in 4 patients previously treated with cisplatin. Major toxic effects observed were hematotoxicity including thrombocytopenia (59.0%), leukopenia (68.9%) and anemia (57.4%) and gastrointestinal toxicity such as nausea and vomiting (63.9%) and anorexia (41.0%); since grade 3 or 4 thrombocytopenia was observed with an incidence of 27.9%, careful monitoring seems to be required during the treatment with this product. Abnormal parameter changes on renal function included elevations of BUN (18.0%) and serum creatinine (9.8%). Based on these results, it was concluded that 254-S is a useful anticancer agent for the treatment of esophageal cancer.

Antineoplastic Agents↗
PubMed1990

Early diagnosis of esophageal cancer.

The doubling time of esophageal cancer, as measured by x-ray films, was studied retrospectively. The average doubling time of 19 lesions in 18 cases was 6.7 months, but in three cases the lesions doubled within a month. The developing time of depth of invasion in esophageal cancer in 19 lesions were: from mucosa to submucosa, 16 +/- 7.8 months; submucosa to advanced adventitia, 6.6 +/- 3.8 months; mucosa to advanced adventitia, 21.1 +/- 6.8 months. Lugol-staining endoscopy was effective in detecting not only lesions but also margin lines. Capsulated brushing cytology is also effective and the diagnostic rate was 94.5% in total, and 84.4% in superficial cancer. For early detection of esophageal cancer it is most desirable to have examinations once every six months and a combination of these three methods is recommended.

Esophageal Neoplasms↗
PubMed1988

[Treatment methods for scirrhous carcinoma of the stomach--with special reference to total gastrectomy and chemotherapy in early postoperative period].

The problems existing in surgical treatment methods for scirrhous carcinoma of the stomach include the following: (1) highly advanced cases are frequent, (2) remnants of carcinoma in the proximal line of resection is frequent, and (3) peritoneal dissemination is frequent. Investigations were made on 76 cases of scirrhous carcinoma of the stomach in the care of our department, and the treatment methods in these cases were as follows: 1) Lymph node dissection: Lymphadenectomy of over R2 is performed. 2) Operative methods: When the cancer lesion is in A, AM, M, or MA, and when the proximal line of resection can be made in the excess of 5 cm from the tumor margin, than a sub-total gastrectomy is performed. For cancer lesions in areas other than the above, and for cancer lesions in the above but when the OW cannot be made to measure over 5 cm, a total gastrectomy is performed. In cases in which the cancer invasion extends beyond EGJ and when non-curative resection factors are absent, then an abdomino-thoracic approach is adopted. 3) Chemotherapy: There was some efficacy among the curative resected cases. Since most of the cases result in peritoneal dissemination, chemotherapy is applied during operation and during the early postoperative period.

Adenocarcinoma, Scirrhous↗
PubMed1984

[Esophageal cancer].

The mortality rate in esophageal cancer among male and female is about 7.7 and 2.0, respectively, totaling 4.8 per 100,000 in Japan. This rate is higher in elderly patients over 60 years of age. The progress in esophageal cancer treatment reveals that until 1924, the operative mortality rate was 95% and even in 1932, the rate was still 50%, making this disease difficult to defeat. However, through Nakayama's improvements in operative procedures by Nakayama in 1948, the mortality rate dropped to below 10%. Recent treatment results in Japan show a resectability rate of 56.2%, operative mortality rate of 8.0% and relative 5-year survival rate of 22%. This is due to the fact that the cases were mainly of advanced cancers. For improvement in the treatment results, the detection of early cancer is vital, and practical collaboration on the part of the patient is most important. Besides x-ray and endoscopy, as methods of diagnosis, there is the capsulated brushing cytology and benefit of application of method is highly expected. As factors affecting the operative followed-up results, particularly vascular invasion and existence of lymph node metastasis can be considered and it is desirable that a treatment method with a firm grasp on the degree of advancement in these factors be applied.

Adult↗
PubMed1982

[Phase II study on peplomycin for esophageal cancer].

For the purpose of verifying the effectiveness of peplomycin, one of the derivatives of bleomycin, against carcinoma of the esophagus and the safety of it, the analysis of the data for total 113 cases collected from 25 institutions in Japan was made. The results are as follows. It was effective in 19 out of 74 evaluable cases of carcinoma of the esophagus (25.7%). In case of treatment with peplomycin alone, it was effective in 6 out of 39 cases (15.4%). In case of the combination treatment with peplomycin and some other therapy, it was effective in 13 out of 35 cases (37.1%). As for the side effects, the incidence of fever was the highest in both the cases of peplomycin alone and the combination treatment such as 39.6% and 37.0%, respectively. Anorexia, nausea, vomiting, respiratory symptoms and tiredness were found in relatively many cases. In the clinical laboratory tests, the vital capacity after the treatment tended to be lower than that before the treatment, but there was little change in the hematological tests, pulmonary function test and renal function test.

Adult↗